INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On August1, 2017,Incyte Corporation issued a press release announcing financial results for its second fiscal quarter ended June30, 2017. The full text of the press release is furnished as Exhibit99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

ExhibitNo.

Description

99.1

Press release issued by Incyte Corporation dated August1, 2017.


INCYTE CORP Exhibit
EX-99.1 2 a17-18626_1ex99d1.htm EX-99.1 Exhibit 99.1     Incyte Reports 2017 Second-Quarter Financial Results and  Updates on Key Clinical Programs   ·                  $276 million of 2017 second-quarter net product revenues from Jakafi® (ruxolitinib),…
To view the full exhibit click here

About INCYTE CORPORATION (NASDAQ:INCY)

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company’s pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company’s second oral JAK1 and JAK2 inhibitor is baricitinib.